Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Vikas Sinha Sells 4,328 Shares

Key Points

• Vikas Sinha, a director at Verona Pharma PLC, sold 4,328 shares of the company for approximately $56,870, reducing his ownership by 4.40% to 94,112 shares.
• Shares of Verona Pharma PLC saw a slight decline of 0.1%, trading at $105.40, with a market cap of $8.97 billion and a PE ratio of -52.70.
• Recent analyst ratings reflect a shift with several firms downgrading Verona Pharma's stock, resulting in a consensus "Hold" rating and an average target price of $109.00.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) Director Vikas Sinha sold 4,328 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $56,869.92. Following the sale, the director owned 94,112 shares in the company, valued at approximately $1,236,631.68. This trade represents a 4.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Verona Pharma PLC American Depositary Share Stock Down 0.1%

Shares of NASDAQ:VRNA traded down $0.07 during midday trading on Tuesday, hitting $105.40. 861,362 shares of the company's stock traded hands, compared to its average volume of 8,219,019. The company has a debt-to-equity ratio of 1.07, a quick ratio of 8.73 and a current ratio of 8.86. The company has a market cap of $8.97 billion, a PE ratio of -52.70 and a beta of 0.12. The firm's fifty day moving average price is $94.93 and its two-hundred day moving average price is $74.38. Verona Pharma PLC American Depositary Share has a twelve month low of $19.45 and a twelve month high of $105.50.

Hedge Funds Weigh In On Verona Pharma PLC American Depositary Share

Several hedge funds and other institutional investors have recently made changes to their positions in VRNA. NBC Securities Inc. acquired a new position in shares of Verona Pharma PLC American Depositary Share during the 1st quarter valued at $34,000. Geneos Wealth Management Inc. lifted its holdings in shares of Verona Pharma PLC American Depositary Share by 44.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after acquiring an additional 193 shares in the last quarter. Vermillion Wealth Management Inc. purchased a new stake in Verona Pharma PLC American Depositary Share during the 4th quarter worth $46,000. Acadian Asset Management LLC purchased a new stake in Verona Pharma PLC American Depositary Share during the 1st quarter worth $48,000. Finally, IFP Advisors Inc purchased a new stake in Verona Pharma PLC American Depositary Share during the 2nd quarter worth $52,000. Institutional investors and hedge funds own 85.88% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Cowen lowered shares of Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a research report on Wednesday, July 9th. TD Cowen lowered shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 9th. Truist Financial lowered shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Wednesday, July 9th. BTIG Research lowered shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 10th. Finally, Wells Fargo & Company lowered shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and decreased their price target for the company from $138.00 to $107.00 in a report on Thursday, July 10th. Eleven research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $109.00.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.